eprintid: 10117138
rev_number: 20
eprint_status: archive
userid: 608
dir: disk0/10/11/71/38
datestamp: 2020-12-14 10:56:08
lastmod: 2022-01-22 23:47:49
status_changed: 2020-12-14 10:56:08
type: article
metadata_visibility: show
creators_name: Seoane-Viaño, I
creators_name: Ong, JJ
creators_name: Luzardo-Álvarez, A
creators_name: González-Barcia, M
creators_name: Basit, AW
creators_name: Otero-Espinar, FJ
creators_name: Goyanes, A
title: 3D printed tacrolimus suppositories for the treatment of ulcerative colitis
ispublished: inpress
divisions: UCL
divisions: B02
divisions: C08
divisions: D10
divisions: G08
keywords: 3D printed drug products, Semi-solid extrusion 3D printing, Inflammatory bowel disease, Suppository drug delivery, Pressure assisted syringe, M3dimaker
note: © 2020 Shenyang Pharmaceutical University. Published by Elsevier B.V.. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
abstract: Ulcerative colitis is a global health problem, affecting millions of individuals worldwide. As an inflammatory condition localised in the large intestine, rectal delivery of immunosuppressive therapies such as tacrolimus is a promising strategy to maximise drug concentration at the site of action whilst minimising systemic side effects. Here, for the first time, self-supporting 3D-printed tacrolimus suppositories were prepared without the aid of moulds using a pharmaceutical semi-solid extrusion (SSE) 3D printer. The suppositories were printed vertically in three different sizes using combinations of two lipid pharmaceutical excipients (Gelucire 44/14 or Gelucire 48/16) and coconut oil. Although both suppository formulations had the appropriate viscosity characteristics for printing, the Gel 44 formulation required less energy and force for extrusion compared to the Gel 48 system. The Gel 44 disintegrated more rapidly but released tacrolimus more slowly than the Gel 48 suppositories. Although the tacrolimus release profiles were significantly different, both suppository systems released more than 80% drug within 120 min. DSC and XRD analysis was inconclusive in determining the solid-state properties of the drug in the suppositories. In summary, this article reports on the fabrication of 3D printed self-supporting suppositories to deliver personalised doses of a narrow therapeutic index drug, with potential benefits for patients with ulcerative colitis.
date: 2020-07-09
date_type: published
official_url: https://doi.org/10.1016/j.ajps.2020.06.003
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1816362
doi: 10.1016/j.ajps.2020.06.003
lyricists_name: Basit, Abdul
lyricists_name: Goyanes, Alvaro
lyricists_name: Ong, Jun Jie
lyricists_id: ABASI56
lyricists_id: AGGOY39
lyricists_id: JJONG36
actors_name: Basit, Abdul
actors_name: Harris, Jean
actors_id: ABASI56
actors_id: JAHAR68
actors_role: owner
actors_role: impersonator
full_text_status: public
publication: Asian Journal of Pharmaceutical Sciences
citation:        Seoane-Viaño, I;    Ong, JJ;    Luzardo-Álvarez, A;    González-Barcia, M;    Basit, AW;    Otero-Espinar, FJ;    Goyanes, A;      (2020)    3D printed tacrolimus suppositories for the treatment of ulcerative colitis.                   Asian Journal of Pharmaceutical Sciences        10.1016/j.ajps.2020.06.003 <https://doi.org/10.1016/j.ajps.2020.06.003>.    (In press).    Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10117138/1/1-s2.0-S1818087620302920-main.pdf